Theratechnologies Inc Stock Price, News & Analysis

Theratechnologies Inc. (THTX) unveiled promising preclinical data for its investigational peptide drug conjugate, sudocetaxel zendusortide (TH1902), during the 2023 AACR meeting. The data suggest that this candidate can enhance immune cell infiltration in 'cold' tumors and boost efficacy alongside PD-L1 checkpoint inhibitors. In melanoma models, the combination of sudocetaxel zendusortide and PD-L1 therapy showed improved tumor inhibition and survival rates. In breast cancer models, it achieved complete tumor regression, outperforming docetaxel and Herceptin combinations. The expression of SORT1, targeted by TH1902, was noted in 60-75% of TNBC and HER2+ cases, supporting its development. The FDA has granted fast track designation for TH1902, although a Phase 1 trial is currently on hold pending protocol amendments.

Theratechnologies announced its Q1 2023 results, reporting a consolidated revenue increase of 7.3% to $19.9 million, driven by a 9% rise in EGRIFTA SV sales and a 5% increase in Trogarzo revenue. The company confirmed its FY2023 revenue guidance of $90 million to $95 million, reflecting a growth range of 13% to 19%. Theratechnologies plans to file an amended protocol for the TH1902 Phase 1 trial by the end of April 2023, following a voluntary enrollment pause. However, the company faced a net loss of $10.4 million and reported increased R&D expenses of $9.4 million. Adjusted EBITDA was $(3.9 million), showing improvement from the previous year. The company is focused on improving operational efficiency and controlling costs.